Your briefing

‘Proposal objected by one particular country’: MEA on why Rajnath Singh refused to sign SCO statement - details
India declined to endorse the joint statement at the SCO Defence Ministers' meeting in Qingdao due to the omission of its terrorism concerns. Defence ...
India 1 week ago
‘Proposal objected by one particular country’: MEA on why Rajnath Singh refused to sign SCO statement - details
Full Coverage

Amazon's 3 secret advantages that could power its stock higher
Finance 1 week ago
Amazon's 3 secret advantages that could power its stock higher
Full Coverage

Danone buys Belgian biotics firm The Akkermansia Company
Finance 1 week ago
Danone buys Belgian biotics firm The Akkermansia Company
Full Coverage

FedEx Just Hiked Its Dividend 5%. Should You Buy FDX Stock Here?
Finance 1 week ago
FedEx Just Hiked Its Dividend 5%. Should You Buy FDX Stock Here?
Full Coverage

Trending

1. Joann's closing
2. Texas Tech basketball
3. UNC basketball
4. Monster Hunter Wilds
5. Ketamine
6. Macron
7. UPMC Memorial shooting
8. Eagles
9. Hims stock
10. Joel Embiid

Popular News

The mortgage market hopes for rate cuts amid war moves
1 week ago
The mortgage market hopes for rate cuts amid war moves

BrightGene präsentiert positive Phase-2-Daten für den Dual-G...
1 week ago
BrightGene präsentiert positive Phase-2-Daten für den Dual-GLP-1R/GIPR-Agonisten zur Gewichtsregulation und Behandlung von Typ-2-Diabetes sowie präklinische Daten für ein neues Amylin-Analogon bei den 85 Wissenschaftlichen Sitzungen der American Diabetes Association

Ukraine returns bodies of 3 Russian soldiers repatriated as ...
1 week ago
Ukraine returns bodies of 3 Russian soldiers repatriated as remains of Ukrainians, Interior Ministry says

BrightGene presenteert positieve fase 2 gegevens voor de dua...
1 week ago
BrightGene presenteert positieve fase 2 gegevens voor de duale GLP-1R/GIPR agonist voor gewichtsbeheersing en type 2 diabetes, en preklinische gegevens voor een nieuw amylin-analoog tijdens de 85e wetenschappelijke sessies van de American Diabetes Association

BrightGene présente des données positives de phase 2 pour so...
1 week ago
BrightGene présente des données positives de phase 2 pour son agoniste double GLP-1R/GIPR dans la gestion du poids et le diabète de type 2, ainsi que des données précliniques pour un nouvel analogue de l'amylin, lors de la 85 e édition des Sessions Scientifiques de l'American Diabetes Association
About Us · Contact Us · Terms & Conditions · Help · Privacy ·

© Latest News Search Engine - Global and Local Breaking News 2025. All rights are reserved